Northway Biotech
24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
Gedeon Richter Launches Online Platform for Transdiagnostic Global Impression Scales and New Caregiver Book at Next Step Conference29.9.2026 14:00:00 CEST | Press release
BUDAPEST, HU / ACCESS Newswire / September 29, 2026 / Gedeon Richter welcomed 145 participants from 27 countries to the latest edition of Next Step, the company's international conference for psychiatrists, held in September at the Hungarian Academy of Sciences. "At Gedeon Richter, we see partnerships as a cornerstone of advancing psychiatric care. By supporting healthcare professionals, patients, and caregivers alike, we can help create meaningful improvements in outcomes, functioning, and quality of life for people living with mental health conditions," said Kristóf Kóczián, Head of Global Business Development and CNS Business Unit at Gedeon Richter in his opening speech. The scientific programme explored how psychiatric care can move beyond diagnostic labels and adopt a more personalized, measurement-based approach. The presentations highlighted how personalized, measurement-based care can be integrated into everyday clinical practice, with a focus on cognitive symptoms, treatment-r
U.S. Polo Assn. Brings 'Game On' to Life with the 2026 Fall-Winter Global Collection29.9.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / September 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), has launched its 2026 Fall-Winter Global Collection, a modern expression of American style rooted in the heritage and energy of the sport of polo. Photographed in the beautiful countryside of Millbrook, New York, the campaign blends the sophistication of New York lifestyle with the authenticity of Hudson Valley's equestrian heritage. From local gathering places and small-town Americana to scenic polo fields and countryside settings, the location creates a natural backdrop for ‘Game On,' a seasonal story inspired by campus life, sport, and polo's enduring style. "The 2026 Fall-Winter Global Collection reflects what makes U.S. Polo Assn. distinctive: an authentic connection to the sport, a modern American point of view and style designed for real life," said J. Michael Prince, President and CEO of USPA Global, the company that manages and
Akkodis and Biolevate Partner to Accelerate AI-Powered Scientific, Regulatory and Technical Documentation in Highly Regulated Industries29.9.2026 06:45:00 CEST | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, and Biolevate, an AI-powered life sciences company, today announced a strategic partnership to accelerate AI-assisted scientific, regulatory and technical documentation in highly regulated industries. Initially launching in France and Belgium, with plans for expansion into additional markets, the partnership combines Biolevate's AI platform with Akkodis' engineering, validation and regulatory expertise to help organizations improve compliance, reduce documentation burdens and accelerate innovation. In highly regulated industries, scientific, technical and compliance-related documentation is critical to product approvals, quality, patient safety and operational compliance. As documentation volumes increase, organizations continue to struggle with manual, resource-intensive processes that are difficult to scale. The result is a pressing nee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom